Oracle Health Sciences Translational Research Center to Support Cancer Research UK's Development of Targeted Cancer Therapies
July 17, 2012
Redwood Shores, Calif. – July 16, 2012
To support its vision of beating cancer in the United Kingdom, Cancer Research UK, the world’s largest not-for-profit cancer research organization, will be working with Oracle Health Sciences Translational Research Center as the foundation for a new analytical environment that will help the charity combine the genetic and clinical data from its Stratified Medicine Programme.
Together with AstraZeneca, Pfizer and the UK government's Technology Strategy Board, Cancer Research UK is working to demonstrate a national service that will provide standardized, high-quality and cost-effective genetic testing of tumors linked to clinical data. This system has already tested two thousand tumors from patients across 24 clinical sites, and set up data capture covering diagnostics, genetics, treatment and outcomes.
Cancer Research UK will use Cohort Explorer which is part of the Oracle Health Sciences Translational Research Center to create a flexible, web-accessible analytical platform and interface that enables program affiliates to effectively and rapidly search and retrieve anonymized diagnostic, treatment and outcome data to accelerate research.
The platform will enable researchers and physicians to gain the insight needed to identify patient populations with similar characteristics and advance personalized cancer treatments.
“Our new analytical platform, which we are building with Oracle Health Sciences Translational Research Center, is an exciting addition to the future of our Stratified Medicine Programme and its goal of combining genetic testing of tumors with clinical data capture to determine more effective treatment,” said Monica Jones, Enterprise Architect and Informatics Lead, Cancer Research UK’s Stratified Medicine Programme.
“Organizations committed to advancing medical science require powerful analytical solutions to reveal insight that was previously locked away at the molecular level,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “Oracle Health Sciences Translational Research Center provides a robust foundation for Cancer Research UK’s analytical environment that will enable it to extend genetic testing of tumors and ultimately advance the development of more targeted and effective treatments.”